Levopidon

Levomethadone Hydrochloride, the active ingredient in Levopidon, is a synthetic opioid presented as an oral tablet for oral use. It is used to manage opioid dependence and chronic pain in adult patients.

GNH USA supplies Levopidon as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levopidon is a synthetic opioid that acts on the μ‑opioid receptor pathway to treat conditions related to opioid use and pain. - Opioid dependence: suppresses withdrawal symptoms and supports maintenance therapy. - Chronic pain: provides analgesia for moderate to severe persistent pain. - Opioid substitution therapy: facilitates transition to a controlled opioid regimen.

Levomethadone may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Nausea: feeling of stomach upset. - Constipation: reduced bowel movements. - Dizziness: light‑headed sensation. - Sedation: increased sleepiness.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - QT interval prolongation: potential cardiac arrhythmia. - Severe allergic reaction: rash, swelling, or anaphylaxis.

Levomethadone requires careful monitoring due to its potency and risk profile. - Respiratory assessment: evaluate breathing function before initiation. - Dependence monitoring: watch for signs of misuse or addiction. - Hepatic impairment: use caution and consider dose adjustment. - Concomitant CNS depressants: avoid or limit use with benzodiazepines or alcohol. - Renal impairment: adjust dosing as needed. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Levomethadone can interact with several drug classes, affecting safety and efficacy.

Major Interactions (Avoid): - Other opioids: increased risk of respiratory depression. - Central nervous system depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory effects. - Monoamine oxidase inhibitors: potential for serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may raise levomethadone levels. - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic effect. - QT‑prolonging agents (e.g., certain antiarrhythmics): monitor cardiac rhythm.